Rigourd Virginie, de Villepin Brune, Amirouche Ammar, Bruneau Alexandra, Seraissol Patrick, Florent Aurelie, Urien Saik, Magny Jean-Francois, Serreau Raphael
*Human Milk Bank Ile de France, Paris; †Medic-Al Network, Necker Hospital, AP-HP, Paris; ‡Pharmacokinetic and Clinical Toxicology Purpan Hospital, Toulouse; and §Cochin Necker Hospital Clinical Research Unit, AP-HP, Paris, France.
Ther Drug Monit. 2014 Oct;36(5):590-6. doi: 10.1097/FTD.0000000000000058.
Analgesics are one of the most prescribed drugs during the postpartum period to prevent and treat pain and inflammatory disease. The focus on analgesics during breastfeeding has increased because of lack of information and fatal codeine intoxication in a breastfed neonate. Ibuprofen has an advantageous benefit-risk ratio profile compared with codeine. There is a lack of information on drug transfer into human milk, thus ibuprofen intake during breastfeeding may be debated. Consequently, there is a dilemma whether to terminate breastfeeding or drug therapy. The objective of this study was to determine the relative infant dose of ibuprofen.
The first week after the delivery, each woman received ibuprofen to treat pain or inflammatory disorders (mean dose, 1012 ± 96 mg/d). Just after the third dose of ibuprofen, 1 milk sample and 2 blood samples were obtained after 1 week of breastfeeding. Ibuprofen concentrations in breast milk and blood were measured by using high-performance liquid chromatography.
Twenty women were included after written informed consent, and 13 gave their breast milk and blood samples. The mean ibuprofen milk concentration was 360 ± 160 mcg/L. The mean fat milk concentration was 3.23 ± 1.15 g per 100 mL, and the mean milk protein concentration 0.87 ± 0.27 g per 100 mL. The ibuprofen transfer infant dose (theoretical infant dose) was 68 mcg·kg-1·d-1 (8-262 mcg·kg-1·d-1), and the relative infant dose was <0.38% (0.04%-1.53%) of the weight-adjusted maternal daily dose, which equals 0.2% of the infant dose.
The results confirm that the transfer of ibuprofen into breast milk decreases with the protein concentration and the duration of lactation. These results suggest that the use of ibuprofen is compatible with prolonged breastfeeding after the early postpartum stage.
镇痛药是产后预防和治疗疼痛及炎症性疾病时最常开具的药物之一。由于信息缺乏以及一名母乳喂养新生儿发生致命的可待因中毒事件,母乳喂养期间对镇痛药的关注有所增加。与可待因相比,布洛芬具有有利的效益风险比。关于药物向人乳中的转移情况缺乏相关信息,因此母乳喂养期间服用布洛芬可能存在争议。因此,面临着是终止母乳喂养还是停止药物治疗的两难境地。本研究的目的是确定布洛芬的相对婴儿剂量。
分娩后的第一周,每位女性服用布洛芬以治疗疼痛或炎症性疾病(平均剂量,1012±96毫克/天)。在服用第三剂布洛芬后,母乳喂养1周后采集1份乳汁样本和2份血液样本。采用高效液相色谱法测定母乳和血液中的布洛芬浓度。
20名女性在签署书面知情同意书后被纳入研究,其中13名提供了母乳和血液样本。母乳中布洛芬的平均浓度为360±160微克/升。每100毫升母乳中脂肪的平均浓度为3.23±1.15克,蛋白质的平均浓度为0.87±0.27克/100毫升。布洛芬的转移婴儿剂量(理论婴儿剂量)为68微克·千克⁻¹·天⁻¹(8 - 262微克·千克⁻¹·天⁻¹),相对婴儿剂量占体重调整后的母亲每日剂量的比例<0.38%(0.04% - 1.53%),相当于婴儿剂量的0.2%。
结果证实,布洛芬向母乳中的转移随蛋白质浓度和哺乳期的延长而降低。这些结果表明,产后早期过后使用布洛芬与延长母乳喂养是相容的。